Skip to content
    Clinical Trials

    Adjuvant Radiotherapy vs Observation After Resection of WHO Grade 2 Atypical Meningioma

    Jenkinson et alThe Lancet

    Adjuvant Radiotherapy vs Observation After Resection of WHO Grade 2 Atypical Meningioma
    Findings from the international, multicentre, open-label, phase 3 randomised controlled trial (ROAM/EORTC-1308) demonstrate that adjuvant radiotherapy should be considered following complete surgical resection of WHO grade 2 atypical meningioma.
    The trial evaluated postoperative radiotherapy versus observation, establishing that adjuvant radiation therapy benefits patients by reducing atypical meningioma recurrence. However, clinicians must weigh the reduction in recurrence risk against the potential delayed adverse effects associated with radiotherapy. Management strategies and decisions regarding adjuvant intervention should be tailored through individualized discussions with each patient.

    Key Takeaways

    • Adjuvant radiotherapy following complete surgical resection of WHO grade 2 atypical meningioma reduces tumor recurrence compared with observation.
    • Treatment decisions should be individualized, balancing the benefit of recurrence prevention against the risk of potential delayed adverse effects of radiotherapy.